Achromatopsia
12
2
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Natural History Study of Inherited Retinal Diseases
PBA Use for Treatment of ATF6-/- Patients
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
Inherited Retinal Degenerative Disease Registry
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
Natural History Study for Achromatopsia
Gene Therapy for Achromatopsia (CNGB3)
Gene Therapy for Achromatopsia (CNGA3)
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
Clinical and Genetic Characterization of Individuals With Achromatopsia
CNTF Implants for CNGB3 Achromatopsia